Teva CEO exits in ongoing crisis of confidence at drugmaker
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- Kroger (KR) To Cut Corporate Workforce By About 3,000 Over 3 Years - Bloomberg
Mizuho Reiterates Neutral Rating for Teva (TEVA) Following CEO Departure
February 7, 2017 5:38 AM ESTMizuho Securities analyst Irina Koffler maintains Neutral rating and $40 price target on Teva Pharmaceuticals (NYSE: TEVA) suggesting management change may not impact stock performance. Chairman of the Board, Dr. Yitzhak Peterburg, will begin serving as President and Interim CEO immediately.
Koffler comments, Teva... More



